Form 4: Director Brian Yoor Receives RSU Grant at iRhythm

Director Brian Yoor was granted 1,573 restricted stock units as part of iRhythm Holdings, Inc.'s equity compensation program.

Summary

• Director Brian Yoor acquired 1,573 restricted stock units (RSUs) on May 27, 2026.
• Each RSU represents a contingent right to receive one share of iRhythm Holdings, Inc. (IRTC) common stock.
• The RSUs vest on the earlier of one year from the grant date or the date of the next annual meeting.
• Following this transaction, the director's total beneficial ownership is 7,171 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Standard market risks associated with equity holdings in the medical technology sector.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term oversight and strategic alignment in the healthcare technology sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for publicly traded medical device companies.
• Vesting schedules tied to annual meetings are common practice to ensure director retention through the annual cycle.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation.

Next Steps

• Vesting of the granted RSUs on the earlier of May 27, 2027, or the date of the next annual meeting.

Key Dates

Keywords

iRhythm, IRTC, Form 4, Director Compensation, Equity Grant, Insider Transaction